<?xml version='1.0' encoding='utf-8'?>
<document id="24472401"><sentence text="Pharmacokinetics and tolerability of olmesartan medoxomil plus hydrochlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation."><entity charOffset="37-57" id="DDI-PubMed.24472401.s1.e0" text="olmesartan medoxomil" /><entity charOffset="63-82" id="DDI-PubMed.24472401.s1.e1" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.24472401.s1.e0" e2="DDI-PubMed.24472401.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s1.e0" e2="DDI-PubMed.24472401.s1.e1" /></sentence><sentence text="The study is to investigate drug-drug interaction (DDI) between olmesartan medoxomil and hydrochlorothiazide (HCTZ), to confirm bioequivalence (BE) of a new combined formulation and coadministration of separate local tablets, and to receive pharmacokinetics and tolerability of the new combined formulation after multiple doses in healthy Chinese subjects"><entity charOffset="64-84" id="DDI-PubMed.24472401.s2.e0" text="olmesartan medoxomil" /><entity charOffset="89-108" id="DDI-PubMed.24472401.s2.e1" text="hydrochlorothiazide" /><entity charOffset="110-114" id="DDI-PubMed.24472401.s2.e2" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24472401.s2.e0" e2="DDI-PubMed.24472401.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s2.e0" e2="DDI-PubMed.24472401.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24472401.s2.e0" e2="DDI-PubMed.24472401.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24472401.s2.e1" e2="DDI-PubMed.24472401.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24472401.s2.e1" e2="DDI-PubMed.24472401.s2.e2" /></sentence><sentence text="" /><sentence text="The 3-in-1 study was separated into 2 stages" /><sentence text=" Stage 1 is a four-period crossover study" /><sentence text=" 28 healthy subjects were equally randomized into four groups" /><sentence text=" Each group received the four following regimens in a sequence as Latin square (4 × 4) design: A: olmesartan medoxomil; B: HCTZ; C: test drug (new combined formulation); D: reference drugs (co-administration of separate tablets)"><entity charOffset="98-118" id="DDI-PubMed.24472401.s7.e0" text="olmesartan medoxomil" /><entity charOffset="123-142" id="DDI-PubMed.24472401.s7.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24472401.s7.e0" e2="DDI-PubMed.24472401.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s7.e0" e2="DDI-PubMed.24472401.s7.e1" /></sentence><sentence text=" In stage 2, half of 28 subjects were daily dosed with regimen C for 7 days" /><sentence text=" Blood and urine samples were obtained to receive pharmacokinetics of olmesartan and HCTZ, which were analyzed using the BE evaluation method"><entity charOffset="70-80" id="DDI-PubMed.24472401.s9.e0" text="olmesartan" /><entity charOffset="85-89" id="DDI-PubMed.24472401.s9.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24472401.s9.e0" e2="DDI-PubMed.24472401.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s9.e0" e2="DDI-PubMed.24472401.s9.e1" /></sentence><sentence text=" Tolerability was also assessed" /><sentence text="" /><sentence text="All subjects completed the study and nobody reported serious adverse event (SAE)" /><sentence text=" The 90% confidence intervals (CI) of geometric mean ratio (GMR) of log transformed Cmax, AUC0-t, and AUC0-∞ after single dose showed no DDI and claimed BE" /><sentence text=" The mean ratio of accumulation (Ra) (SD) of olmesartan and HCTZ after multiple doses of new combination formulation is 1"><entity charOffset="45-55" id="DDI-PubMed.24472401.s14.e0" text="olmesartan" /><entity charOffset="60-69" id="DDI-PubMed.24472401.s14.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24472401.s14.e0" e2="DDI-PubMed.24472401.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s14.e0" e2="DDI-PubMed.24472401.s14.e1" /></sentence><sentence text="03 (0" /><sentence text="182) and 0" /><sentence text="954 (0" /><sentence text="128)" /><sentence text="" /><sentence text="No significant DDI between olmesartan and HCTZ was found"><entity charOffset="27-37" id="DDI-PubMed.24472401.s20.e0" text="olmesartan" /><entity charOffset="42-46" id="DDI-PubMed.24472401.s20.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24472401.s20.e0" e2="DDI-PubMed.24472401.s20.e0" /><pair ddi="false" e1="DDI-PubMed.24472401.s20.e0" e2="DDI-PubMed.24472401.s20.e1" /></sentence><sentence text=" The new combination formulation is bioequivalent to co-administration of two separate local tablets" /><sentence text=" After multiple doses of the new combination formulation, no significant accumulation was observed" /><sentence text=" The new combination formulation is reasonably tolerated well in healthy Chinese subjects after multiple doses" /><sentence text="" /></document>